esketamine sintetica 25 mg/ml solution for injection/infusion
sintetica gmbh - esketamine hydrochloride - solution for injection/infusion - esketamine
esketamine sintetica 5 mg/ml solution for injection/infusion
sintetica gmbh - esketamine hydrochloride - solution for injection/infusion - esketamine
esketamine sintetica 25 mg/ml solution for injection/infusion
sintetica ireland limited - esketamine - solution for injection/infusion - 25 milligram(s)/millilitre - esketamine
esketamine sintetica 5 mg/ml solution for injection/infusion
sintetica ireland limited - esketamine - solution for injection/infusion - 5 milligram(s)/millilitre - esketamine
spravato esketamine (as hydrochloride) 28 mg per 2 actuations nasal spray solution
janssen-cilag pty ltd - esketamine hydrochloride, quantity: 32.3 mg (equivalent: esketamine, qty 28 mg) - spray, nasal - excipient ingredients: disodium edetate; citric acid monohydrate; water for injections; sodium hydroxide - spravato is indicated for treatment resistant depression (major depressive disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode).,spravato is to be initiated in conjunction with a newly initiated oral antidepressant.
esketamine kalceks 5 mg/ml inj./inf. sol. i.v./i.m. amp.
as kalceks a.s. - esketamine hydrochloride 5,77 mg/ml - eq. esketamine 5 mg/ml - solution for injection/infusion - 5 mg/ml - esketamine hydrochloride 5.77 mg/ml - esketamine
esketamine kalceks 25 mg/ml inj./inf. sol. i.v./i.m. amp.
as kalceks a.s. - esketamine hydrochloride 28,85 mg/ml - eq. esketamine 25 mg/ml - solution for injection/infusion - 25 mg/ml - esketamine hydrochloride 28.85 mg/ml - esketamine
esketamine kalceks 25 mg/ml inj./inf. sol. i.v./i.m. amp.
as kalceks a.s. - esketamine hydrochloride 28,85 mg/ml - eq. esketamine 25 mg/ml - solution for injection/infusion - 25 mg/ml - esketamine hydrochloride 28.85 mg/ml - esketamine
spravato solution
janssen inc - esketamine (esketamine hydrochloride) - solution - 28mg - esketamine (esketamine hydrochloride) 28mg - miscellaneous antidepressants
spravato- esketamine hydrochloride solution
janssen pharmaceuticals inc. - esketamine hydrochloride (unii: l8p1h35p2z) (esketamine - unii:50lfg02txd) - spravato ® is indicated, in conjunction with an oral antidepressant, for the treatment of: - treatment-resistant depression (trd) in adults - depressive symptoms in adults with major depressive disorder (mdd) with acute suicidal ideation or behavior limitations of use: - the effectiveness of spravato in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated [see clinical studies (14.2)] . use of spravato does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of spravato. - spravato is not approved as an anesthetic agent. the safety and effectiveness of spravato as an anesthetic agent have not been established. spravato is contraindicated in patients with: - aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation [see warnings and precautions (5.7)] - history of intracere